Crispr Therapeutics reports Q4 EPS ($1.37), consensus ($1.23)

Reports Q4 revenue $864K, consensus $4.02M. “As we close out the fourth quarter, Crispr Therapeutics (CRSP) continues to make steady progress across a broad and increasingly mature pipeline,” said Samarth Kulkarni, Ph.D., CEO. “We made meaningful advances across multiple clinical and preclinical programs, including encouraging data from zugo-cel in autoimmune disease and oncology, continued global uptake of CASGEVY, and important developments across our in vivo liver editing portfolio, and momentum in our siRNA collaboration with Sirius Therapeutics. At the same time, we continue to strengthen our platform capabilities to support long-term value creation. Together, these developments reflect continued execution across the portfolio.”